Home › Glioblastoma › Ohio
Glioblastoma clinical trials in Ohio
23 studies for Glioblastoma are looking for participants at sites in Ohio.
Cities in Ohio
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Cleveland Clinic Taussig Cancer Center, Cleveland
- Ohio State University, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07326566Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05432804Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- The Ohio State University, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07195591Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Neurological Institute Brain Tumor Centre Taussig Cancer Cente, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05902169hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT05052957Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
- Case Western Reserve University, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07452458Targeted Pediatric High-Grade Glioma Therapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT05565118A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07003542A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- University Hospitals Cleveland Medical Center*, Cleveland
- Cleveland Clinic, Cleveland
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT03970447Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- Ohio State University Medical Center, Columbus
Recruiting
Ages 18 to 85 · All sexes · Updated Jul 21, 2026 · NCT06910306Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
- Ohio State University, Columbus
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jul 17, 2026 · NCT07225621DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
- Ohio State University Hospital, Columbus
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Jun 12, 2026 · NCT07346144Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544Sacituzumab Govitecan in Recurrent Glioblastoma
- Cleveland Clinic Taussig Cancer Center, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT04559230SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- The Cleveland Clinic, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 25, 2025 · NCT05879367From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.